Manzo Pharmaceuticals announces progress, as retail stores start to carry Tummy Relief.

MILFORD, Pa., March 9, 2015 /PRNewswire/ -- Manzo Pharmaceuticals, Inc. (OTCPink: MNZO), today announced its first retail product, Tummy Relief™ is now carried at Esterbrook Pharmacy in Reading, Pennsylvania, as the start of a major push into brick and mortar retail. 

Kenneth Manzo, The Company's CEO, stated that he is actively promoting the product, and is continuing the process of initiating talks with major retail chains to carry the product nationwide. "It's time to start pushing forward with the distribution of Tummy Relief™. As a Licensed Pharmacist, I feel this is a superior product to anything on the market, and the time has come to get it in the hands of consumers," said Mr. Manzo.

Another reason for Manzo to be excited is in regards to the company's Lacto-Freedom™ product. The recent 6-month lab rat study found that intestinal lactase levels were significantly higher in the treated groups as compared to the untreated groups.  The 3-month lactase levels were higher than the 6-month results showing a decline in lactase production over time. At 3-months after the probiotic was given, intestinal lactase levels increased 900% with the lowest dose of Lacto-Freedom and 2400% with the highest dose.  At the 6-month mark, the lowest dose increased lactase levels by 450% and the highest dose increased lactase levels by 1000%. In addition, there were no negative side effects even at very high doses of Lacto-Freedom probiotic making the products outlook extremely positive, and better than expected. Mr. Manzo explains that the details that have been given so far have been intentionally vague due to the fact that the company plans to submit a new patent with the new data that was obtained during this most recent six-month test. One of the strategies of the company is to seek support from dairy product manufacturers, since if Lacto-Freedom™ does what it has shown it is capable of so far in the lab, it should create a huge increase in the demand for dairy products benefitting manufacturers greatly.

Lastly, the company is happy to announce that it has recently submitted a form1-a to the Securities and Exchange Commission as part of a planned offering the company has put together with a privately operated investment fund to raise capital. The fund will be used to finance a human clinical study, and to repay existing debt that was generated to pay for the recent six month animal study as well as to cover the costs of running a publicly traded company. The funds will also be used for continued development and marketing of the Lacto-Freedom™ probiotic. The company confirms that this is the reason for the recent increase in authorized shares from 950 Million to 1.9 Billion, which it did under advisement from William Eilers of Eiler's Law, the firm handling the preparation and legal opinion for the offering.   

For more information listen to the CEO, Kenneth Manzo on the popular internet radio show, The Stock Radio on Tuesday March 10^th where he will be discussing the latest developments.

About Manzo Pharmaceuticals, Inc.

Manzo Pharmaceuticals, Inc. is a specialty pharmaceutical company engaged in the research, development, and testing of patented and non-patented solutions and remedies. Most notably is a patented solution for lactose Intolerance, and a natural remedy for colic in babies. For more information follow the company on twitter at @manzopharma, and visit www.manzopharma.com.  

DISCLAIMER:

This Press Release may contain certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The Company has tried, whenever possible, to identify these forward-looking statements using words such as "anticipates," "believes," "estimates," "expects," "plans," "intends," "potential" and similar expressions. These statements reflect the Company's current beliefs and are based upon information currently available to it. Accordingly, such forward-looking statements involve known and unknown risks, uncertainties and other factors which could cause the Company's actual results, performance or achievements to differ materially from those expressed in or implied by such statements. The Company undertakes no obligation to update or advise in the event of any change, addition or alteration to the information catered in this Press Release including such forward-looking statements.

SOURCE Manzo Pharmaceuticals, Inc.

Related Links

http://www.manzopharma.com